Percheron Therapeutics (ASX:PER) FCF Yield %: -211.19 (As of Jun. 25, 2026)


What is Percheron Therapeutics FCF Yield %?

Percheron Therapeutics ASX:PER FCF Yield % is -211.19 as of Jun. 25, 2026. The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Percheron Therapeutics ranks worse than 99.2% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Percheron Therapeutics's Trailing 12-Month Free Cash Flow is A$-12.86 Mil, and Market Cap is A$6.09 Mil. Therefore, Percheron Therapeutics's FCF Yield % for today is -211.19%.

The historical rank and industry rank for Percheron Therapeutics's FCF Yield % or its related term are showing as below:

ASX:PER' s FCF Yield % Range Over the Past 10 Years
Min: -276.37   Med: -20.67   Max: 25.26
Current: -211.19


During the past 13 years, the highest FCF Yield % of Percheron Therapeutics was 25.26%. The lowest was -276.37%. And the median was -20.67%.

ASX:PER's FCF Yield % is ranked worse than
99.2% of 1005 companies
in the Drug Manufacturers industry
Industry Median: 0.67 vs ASX:PER: -211.19

Percheron Therapeutics's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.


Percheron Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Percheron Therapeutics FCF Yield % Related Terms


Percheron Therapeutics FCF Yield % Historical Data

* Premium members only.

The historical data trend for Percheron Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Percheron Therapeutics FCF Yield % Chart

Percheron Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.08 -15.16 -20.18 -12.86 -140.18

Percheron Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.41 -13.64 -216.89 -128.53 -113.18

ASX:PER vs ZTS: FCF Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Percheron Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Percheron Therapeutics FCF Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Percheron Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Percheron Therapeutics's FCF Yield % falls into.



Percheron Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Percheron Therapeutics's FCF Yield % for the fiscal year that ended in Jun. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-15.65 / 11.16436
=-140.18%

Percheron Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-5.686 * 2 / 10.047924
=-113.18%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -211.19 mean?
Percheron Therapeutics (ASX:PER) has a FCF Yield % of -211.19 as of Jun. 25, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Percheron Therapeutics and its competitors. According to the industry distribution chart, Percheron Therapeutics ranks #997 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 99.2%.
Is Percheron Therapeutics' FCF Yield % too high?
Percheron Therapeutics' current FCF Yield % is -211.19. Based on the distribution chart, Percheron Therapeutics ranks #997 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Percheron Therapeutics' FCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Percheron Therapeutics ranks #997 out of 1005 companies for FCF Yield %. This places Percheron Therapeutics in the lower half of its industry. The industry median FCF Yield % is 0.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Percheron Therapeutics and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Percheron Therapeutics's current FCF Yield % is -211.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Percheron Therapeutics stock overvalued right now?
Percheron Therapeutics (ASX:PER) has a current FCF Yield % of -211.19. The current FCF Yield % is -211.19. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Percheron Therapeutics (ASX:PER), the current FCF Yield % is -211.19 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Percheron Therapeutics Business Description

Other Exchanges PERCF:USAAWY0:Germany
Address 35 Collins Street, Level 30, Collins Place, Melbourne, VIC, AUS, 3000
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.